SCHEMBL4079868

SCHEMBL4079868

CCCCNC(=O)c1c(NC(=O)C2C(C)(C)C2(C)C)sc2c1CCCC2

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 8/20 0.66
CYP1A2 P05177 2/20 0.59
CYP2C9 P11712 2/20 0.59
CNR1 P21554 3/20 0.58
TP53 P04637 1/20 0.54
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
ATM Q13315 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.51
ALDH1A1 P00352 3/20 0.50
KDM4E B2RXH2 2/20 0.50
CYP3A4 P08684 1/20 0.50
HPGD P15428 1/20 0.50
CYP2C19 P33261 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
RAB9A P51151 1/20 0.47
MAPK10 P53779 1/20 0.47
MAPT P10636 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4094326 0.96 CNR2 (0.63) CNR2CYP1A2CYP2C9CNR1TP53
SCHEMBL4084167 0.93 CNR2 (0.74) CNR2CYP1A2CYP2C9CNR1TP53
SCHEMBL4095565 0.91 CNR2 (0.74) CNR2CYP1A2CYP2C9CNR1TP53
SCHEMBL4080819 0.90 KMT2A (0.60) CNR2CYP1A2CYP2C9CNR1TP53
SCHEMBL4080119 0.89 KMT2A (0.59) CNR2CYP1A2CYP2C9CNR1TP53
SCHEMBL4089814 0.89 CNR2 (0.67) CNR2CYP1A2CYP2C9CNR1TP53
SCHEMBL4090251 0.89 CNR2 (0.62) CNR2CYP1A2CYP2C9CNR1TP53
SCHEMBL4085782 0.89 CYP1A2 (0.71) CNR2CYP1A2CYP2C9CNR1TP53
SCHEMBL21603687 0.88 CNR2 (0.71) CNR2CYP1A2CYP2C9CNR1TP53
SCHEMBL21603765 0.87 CNR2 (0.77) CNR2CYP1A2CYP2C9CNR1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338623-B2 N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBVIE INC. (US) 2012-12-25 US disclosed
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018114-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS CNR1, CNR2, GPR18 CNR2 2/4885CYP1A2 847/4885CYP2C9 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.